Thomas Spitznagel
Corporate Officer/Principal at MACROGENICS, INC.
Net worth: 119 501 $ as of 2024-04-29
Profile
Thomas M.
Spitznagel is currently the Senior Vice President-Technical Operations at MacroGenics, Inc. Prior to his current position, he held the role of Vice President-BioPharmaceutical Development at Human Genome Sciences, Inc. from 1998 to 2012.
He also worked as a Staff Engineer at Genetics Institute LLC from 1992 to 1996 and as a Senior Scientist at Nabi Biopharmaceuticals from 1996 to 1998.
Dr. Spitznagel obtained his undergraduate degree from the Massachusetts Institute of Technology and his doctorate degree from the University of California, Berkeley.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MACROGENICS, INC.
0.01% | 2024-03-03 | 8,316 ( 0.01% ) | 119 501 $ | 2024-04-29 |
Thomas Spitznagel active positions
| Companies | Position | Start |
|---|---|---|
| MACROGENICS, INC. | Corporate Officer/Principal | 2012-12-31 |
Former positions of Thomas Spitznagel
| Companies | Position | End |
|---|---|---|
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 2012-06-30 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Chief Tech/Sci/R&D Officer | 1997-12-31 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 1995-12-31 |
Training of Thomas Spitznagel
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Thomas Spitznagel
